Boxer Capital Management has significantly increased its stake in Vir Biotechnology (NASDAQ: VIR), acquiring 1,241,000 shares valued at approximately $9.89 million, according to a recent SEC filing. This transaction boosts Boxer’s total holdings in Vir to 2.2% of its 13F reportable assets under management as of March 31, 2026, reflecting a $12.95 million increase in position value for the quarter.
Vir Biotechnology has experienced a remarkable resurgence, with its stock price soaring nearly 100% over the past year, significantly outperforming the S&P 500. The company, which focuses on immunology-based therapies for serious infectious diseases, recently reported promising Phase 2 results for its hepatitis delta treatment and is preparing for pivotal Phase 3 trials for its prostate cancer therapy in collaboration with Astellas. With over $809 million in cash reserves, Vir is well-positioned to leverage its pipeline for future growth.
Investors should closely monitor Vir’s ability to convert its financial resources and promising clinical data into sustainable revenue streams, as the market will be watching for signs of continued momentum.
Source: fool.com